Published in J Virol on February 01, 1987
Evaluation of four methods for cytomegalovirus antibody detection for use by a bone marrow transplantation service. J Clin Microbiol (1989) 0.98
Simultaneous detection of antibodies to cytomegalovirus and herpes simplex virus by using flow cytometry and a microsphere-based fluorescence immunoassay. J Clin Microbiol (1988) 0.94
Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine. J Virol (1988) 0.91
Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines. J Clin Microbiol (1990) 0.81
Relay of herpes simplex virus between Langerhans cells and dermal dendritic cells in human skin. PLoS Pathog (2015) 0.78
Sexually transmitted viruses. Yale J Biol Med (1989) 0.75
Fluorographic detection of radioactivity in polyacrylamide gels with the water-soluble fluor, sodium salicylate. Anal Biochem (1979) 22.03
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Causes of the acute urethral syndrome in women. N Engl J Med (1980) 6.91
Infection with herpes-simplex viruses 1 and 2. 1. N Engl J Med (1973) 2.87
Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections. Am J Epidemiol (1970) 2.83
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J Virol (1982) 2.55
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
Measurement of antibodies to herpesvirus types 1 and 2 in human sera. J Immunol (1970) 2.45
Characterization of the 92,000-dalton glycoprotein induced by herpes simplex virus type 2. J Virol (1984) 2.36
Monoclonal antibodies to three non-glycosylated antigens of herpes simplex virus type 2. J Gen Virol (1982) 2.23
Binding to cells of virosomes containing herpes simplex virus type 1 glycoproteins and evidence for fusion. J Virol (1984) 2.21
Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. Am J Med (1984) 2.05
Monoclonal antibodies to two glycoproteins of herpes simplex virus type 2. J Virol (1981) 1.94
Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect Immun (1984) 1.83
Use of monoclonal antibodies against two 75,000-molecular-weight glycoproteins specified by herpes simplex virus type 2 in glycoprotein identification and gene mapping. J Virol (1983) 1.73
Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol (1985) 1.71
Characterization of a herpes simplex virus type 2 75,000-molecular-weight glycoprotein antigenically related to herpes simplex virus type 1 glycoprotein C. J Virol (1983) 1.69
Sexual and socioeconomic factors affecting the risk of past infections with herpes simplex virus type 2. Am J Epidemiol (1983) 1.45
Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest (1984) 1.07
Application of molecular genetics to the design of live herpes simplex virus vaccines. Dev Biol Stand (1982) 0.95
Concept review of genital herpes vaccines. J Infect Dis (1982) 0.92
Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. J Infect Dis (1984) 0.91
Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol (1985) 0.83
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Comparison of HIV-antibody prevalence in patients consenting to and declining HIV-antibody testing in an STD clinic. JAMA (1988) 6.14
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Chronic fatigue in adolescents. Pediatrics (1991) 5.24
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 4.91
Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS (1988) 4.85
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med (1996) 4.28
Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol (1981) 4.10
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
The acquisition of herpes simplex virus during pregnancy. N Engl J Med (1997) 3.73
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ (1994) 3.71
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med (1992) 3.56
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med (1993) 3.51
Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol (1999) 3.48
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med (1996) 3.35
Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med (1980) 3.33
Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med (1981) 3.32
Infections with herpes simplex viruses (1). N Engl J Med (1986) 3.26
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med (1991) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis (2001) 2.79
Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med (1987) 2.74
Sexually transmitted diseases in victims of rape. N Engl J Med (1990) 2.74
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. J Infect Dis (1983) 2.60
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med (1989) 2.56
Chronic fatigue. A prospective clinical and virologic study. JAMA (1990) 2.54
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 2.53
Typing of clinical herpes simplex virus isolates with mouse monoclonal antibodies to herpes simplex virus types 1 and 2: comparison with type-specific rabbit antisera and restriction endonuclease analysis of viral DNA. J Clin Microbiol (1983) 2.50
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med (1983) 2.33
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med (1992) 2.25
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med (1985) 2.23
Infections with herpes simplex viruses (2). N Engl J Med (1986) 2.22
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20
Retracted HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest (2000) 2.17
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol (1997) 2.16
Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med (1991) 2.12
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis (1999) 2.07
Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis (1991) 2.06
Epidemiology of Reye syndrome. Epidemiol Rev (1981) 2.04
Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA (1994) 2.03
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med (1989) 2.03
Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol (1999) 2.02
Monoclonal antibodies for diagnosis of infectious diseases in humans. Science (1983) 2.02
Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med (1993) 2.01
Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01
The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Transm Dis (1990) 2.00
Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic, and histopathological features. N Engl J Med (1983) 1.97
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.97
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA (1984) 1.94